Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-9.73 Insider Own10.43% Shs Outstand3.14M Perf Week16.67%
Market Cap3.30M Forward P/E13.12 EPS next Y0.08 Insider Trans-64.69% Shs Float2.81M Perf Month164.15%
Income-14.39M PEG- EPS next Q-0.01 Inst Own5.77% Short Float0.47% Perf Quarter7.14%
Sales9.71M P/S0.34 EPS this Y78.73% Inst Trans-70.81% Short Ratio0.10 Perf Half Y-16.00%
Book/sh1.47 P/B0.72 EPS next Y101.84% ROA-79.94% Short Interest0.01M Perf Year-66.67%
Cash/sh1.28 P/C0.82 EPS next 5Y- ROE-296.97% 52W Range0.36 - 6.67 Perf YTD74.71%
Dividend Est.- P/FCF- EPS past 5Y36.78% ROI-187.76% 52W High-84.26% Beta2.51
Dividend TTM- Quick Ratio0.57 Sales past 5Y4.44% Gross Margin24.32% 52W Low191.18% ATR (14)0.11
Dividend Ex-Date- Current Ratio0.78 EPS Y/Y TTM68.26% Oper. Margin-60.31% RSI (14)76.86 Volatility12.75% 17.61%
Employees41 Debt/Eq1.94 Sales Y/Y TTM-4.99% Profit Margin-148.16% Recom1.00 Target Price5.00
Option/ShortNo / Yes LT Debt/Eq0.67 EPS Q/Q69.04% Payout- Rel Volume0.22 Prev Close1.05
Sales Surprise-29.23% EPS Surprise-585.71% Sales Q/Q3.74% EarningsNov 13 AMC Avg Volume125.93K Price1.05
SMA2043.54% SMA5068.07% SMA200-3.83% Trades Volume28,069 Change0.00%
Date Action Analyst Rating Change Price Target Change
May-23-18Initiated H.C. Wainwright Buy
Dec-22-15Downgrade Maxim Group Buy → Hold
Nov-17-15Reiterated Maxim Group Buy $7 → $1
Sep-21-15Upgrade H.C. Wainwright Neutral → Buy $2
May-15-15Downgrade H.C. Wainwright Buy → Neutral
Jun-26-14Initiated H.C. Wainwright Buy $5
Apr-24-14Initiated Maxim Group Buy $7
Nov-14-23 10:26AM
Nov-13-23 04:05PM
Nov-08-23 08:31AM
Oct-26-23 04:30PM
08:30AM Loading…
Sep-06-23 08:30AM
Aug-12-23 09:26AM
Aug-11-23 06:48AM
Aug-10-23 04:05PM
Aug-08-23 03:25PM
Jul-17-23 01:20PM
Jul-07-23 08:32AM
May-16-23 10:03AM
May-15-23 04:05PM
May-10-23 08:30AM
05:15PM Loading…
May-04-23 05:15PM
Apr-17-23 08:21AM
Apr-09-23 10:22AM
Apr-02-23 09:08AM
Mar-30-23 04:05PM
Mar-28-23 08:30AM
Mar-20-23 06:31PM
Mar-17-23 11:39AM
Mar-16-23 08:30AM
Mar-15-23 02:12PM
Mar-02-23 07:25PM
Jan-11-23 08:30AM
Dec-21-22 09:08AM
07:32AM Loading…
Nov-13-22 07:32AM
Nov-10-22 07:15PM
Nov-07-22 01:20PM
Oct-28-22 12:47PM
Oct-25-22 09:11PM
Oct-23-22 08:22AM
Oct-11-22 11:54AM
Sep-07-22 08:30AM
Aug-11-22 02:35PM
Aug-09-22 01:43PM
May-19-22 04:05PM
May-18-22 08:30AM
May-15-22 10:58AM
May-09-22 05:25PM
May-05-22 07:15PM
Mar-28-22 04:05PM
Mar-23-22 08:30AM
Mar-14-22 09:35AM
Jan-11-22 01:00PM
Jan-10-22 08:30AM
Dec-17-21 02:16PM
Dec-06-21 12:50PM
Nov-12-21 04:05PM
Nov-05-21 08:30AM
Nov-04-21 03:01PM
Sep-14-21 08:30AM
Sep-07-21 08:30AM
Aug-12-21 06:15PM
Aug-06-21 03:00PM
Aug-05-21 01:50PM
Jun-08-21 07:29AM
May-13-21 04:05PM
May-06-21 08:30AM
Apr-30-21 04:55PM
Mar-17-21 04:05PM
Mar-10-21 08:30AM
Feb-17-21 08:30AM
Feb-03-21 08:30AM
Jan-07-21 08:30AM
Dec-10-20 04:31AM
Nov-12-20 04:05PM
Nov-05-20 08:30AM
Oct-20-20 08:30AM
Sep-11-20 03:34PM
Sep-02-20 08:30AM
Aug-31-20 08:30AM
Aug-14-20 04:05PM
Aug-13-20 08:30AM
Aug-11-20 04:05PM
Aug-05-20 08:30AM
Jun-23-20 01:38PM
Jun-16-20 08:30AM
Jun-11-20 08:30AM
Jun-08-20 01:07PM
May-28-20 02:42PM
May-18-20 08:57AM
May-14-20 04:05PM
May-07-20 08:30AM
Apr-24-20 08:30AM
Apr-16-20 08:45AM
Apr-13-20 08:30AM
Apr-03-20 08:30AM
Apr-02-20 10:33AM
Mar-31-20 08:30AM
Mar-27-20 02:52PM
ThermoGenesis Holdings, Inc. engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. It markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, CAR-Txpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company was founded by Philip H. Coelho in 1986 and is headquartered in Rancho Cordova, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Xu XiaochunCEONov 17Sale1.02600,000612,000327,121Nov 21 07:30 AM